The Motley Fool Discussion Boards

Previous Page

International Investing / Australia (All-Ordinaries)


Subject:  Re: Novogen Date:  4/5/2002  11:47 AM
Author:  jbob100 Number:  4045 of 6186

Hi all,

Please excuse me for posting somethin that is not about NVGN, but I know many of you are interested in cancer. I have been following ALTAREX, a canadian company that has an interesting approach to ovarian cancer using monoclonal antibodies to stimulate a cancer specific immune response. They are also presenting at the AACR this weekend.

I would like to know if anyone would be interested in establishing a new board for ALXFF. Their latest news release is below for your review and comment.


AltaRex Presents OvaRex(R) Data at AACR Conference
PR Newswire, Friday, April 05, 2002 at 09:57


AltaRex Presents OvaRex(R) Data at AACR Conference

OvaRex(R)-Induced T Cells Correlated with Clinical

Benefit in Recurrent Disease Trials

WALTHAM, Mass., April 5 /PRNewswire-FirstCall/ -- AltaRex Corp. (AXO.TO, ALXFF.OTC) announced today that it will make an oral presentation of clinical results from an integrated analysis of two OvaRex(R) clinical studies in recurrent ovarian cancer at the American Association for Clinical Research (AACR) meeting in San Francisco. Birgit Schultes, Ph.D., Executive Director of Research at AltaRex, will discuss data regarding T cell activation and correlated clinical benefit during the "Cancer Vaccines" symposium on Sunday April 7. In the reported studies, OvaRex(R) is active in recurrent disease, tumor burden is not impacting the frequency or quality of immune responses and OvaRex(R) is able to induce cellular responses to CA125 and autologous tumor cells. The T cell responses are correlated with a significant (p=0.0026) increase in time to disease progression.

(Photo: )

The two open-label phase II studies featured in the presentation at AACR were designed to evaluate immune response induction and clinical outcome for recurrent ovarian cancer patients as a result of immunotherapy (13-patient study, Dr. Thomas Ehlen) or combined chemo-immunotherapy (20-patient study, Dr. Alan Gordon) with OvaRex(R) MAb. Primary results of the individual studies have previously been reported by AltaRex (March 2001 and March 2002, respectively). Both studies focused on the induction of cellular responses to CA125 and autologous tumor and also investigated OvaRex(R) activity in the recurrent disease setting.

The integrated analysis demonstrates:

-- Clinical Response at First Assessment:

* After four administrations of OvaRex(R) (week 12-13), 7 of 26 evaluable

patients (27%) achieved a clinical response (3 no evaluable disease, 2

complete response, 2 partial response).

-- Cellular Immune Response:

* 86% of the patients with clinical response (6 of 7) had CA125- and/or

tumor-specific T cell immune responses.

* 59% of the patients evaluable for cellular response (13 of 22)

developed CA125- and/or tumor-specific T cell immune responses.

* T cell responses were generally maintained on combined treatment

(Gordon study) with OvaRex(R) and second-line chemotherapy (platinum,

paclitaxel, Doxil(R)).

-- Humoral Immune Response:

* Of the patients evaluable for humoral response, 71% (22 of 31)

developed robust antibody responses to the constant (HAMA) region, and

60% (18 of 30) to the variable region (Ab2) of OvaRex(R) MAb.

-- Time to Progression and Survival Benefit:

* T cell responders to CA125 and/or autologous tumor demonstrated a

significant benefit over non-responders in median time to progression;

60 weeks for responders (n=13) versus 10.7 weeks for non-responders

(n=9), p=0.0026. Median survival has not yet been reached for

responders (n=13) while median survival for non-responders (n=9) is 38


-- Safety:

* OvaRex(R) infusions were well tolerated. There was no drug related

toxicity and adverse events were non-specific and Grade 2 or less.

"There are two important findings from the recurrent disease studies," commented Christopher Nicodemus, M.D., Senior Vice President of Clinical Research and Development at AltaRex. "First, we are able to activate T cell immunity concurrent to chemotherapy and second, this T cell immunity is associated with a positive clinical outcome. These findings point to the future development potential of OvaRex(R) in conjunction with chemotherapy. This is in addition to the use of OvaRex(R) alone in the period following front-line therapy. We believe that immune modulation with antibody treatments such as OvaRex(R) are a promising non-toxic addition to standard treatment."

For more information about the Company, please visit the AltaRex website at

This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward- looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "intends," "expects" and similar expressions are intended to identify forward-looking statements. Such risks and uncertainties include, but are not limited to our need for capital and the risk that the Company can not raise funds on a timely basis on satisfactory terms or at all, the need to obtain corporate alliances and the risk that the Company cannot establish corporate alliances on a timely basis, on satisfactory terms, or at all, changing market conditions, uncertainties regarding the timely and successful completion of clinical trials, patient enrollment rates, uncertainty of pre-clinical, retrospective, early and interim clinical trial results, which may not be indicative of results that will be obtained in ongoing or future clinical trials, whether the Company will file for regulatory approval on a timely basis, uncertainties as to when, if at all, the FDA will accept or approve the Company's regulatory filings for its products, the need to establish and scale-up manufacturing processes, uncertainty as to the timely development and market acceptance of the Company's products, uncertainty as to whether patents will issue from pending patent applications and, if issued, as to whether such patents will be sufficiently broad to protect the Company's technology, and other risks detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission and Canadian securities authorities. The Company does not assume any obligation to update any forward-looking statement.


SOURCE AltaRex Corp.

-0- 04/05/2002

/CONTACT: Peter Gonze, Operations-Investor Relations, +1-781-672-0138, ext. 1503, [email protected], Sondra Henrichon, Investor Relations, +1-781-672-0138, ext. 1510, [email protected]/

/Company News On-Call:

/Photo: NewsCom:

AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840/

/Web site:

Companies or Securities discussed in this article:
Symbol Name

Back to Company Snapshot

Copyright 1996-2022 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us